Log in or Sign up for Free to view tailored content for your specialty!
Reproduction/Androgen Disorders News
Utilizing machine learning plus clinical features accurately predicted PCOS
DENVER — A prediction model that integrates machine learning-derived measures of ovarian volume, anti-Müllerian hormone levels and other clinically-derived diagnostic endpoints accurately predicted polycystic ovary syndrome.
Making menopause mainstream: A conversation with Monica Christmas, MD, FACOG, MSCP
Interest in menopause and all things related to midlife women’s health continues to grow, and The Menopause Society is expanding to meet the demand.
Log in or Sign up for Free to view tailored content for your specialty!
Screening, referrals needed for overlooked ‘third pillar’ of PCOS: Psychosocial symptoms
After years of advocacy and research, clinicians increasingly recognize the physical symptoms of polycystic ovary syndrome. Yet, many women with PCOS have a range of serious psychosocial comorbidities that often go unaddressed.
FDA accepts new drug application for nonhormonal hot flash drug elinzanetant
The FDA accepted a new drug application for elinzanetant, a nonhormonal treatment for moderate to severe vasomotor symptoms associated with menopause, according to an industry press release.
Q&A: What to know about pregnancy for women with kidney disease
When counseling women with kidney disease about pregnancy, nephrologists and women’s health providers must emphasize intentionality.
Primary ovarian insufficiency more than doubles midlife multimorbidity risk
Women with premature ovarian insufficiency and early menopause have increased multimorbidity compared with women with menopause onset at an average age of 46 to 55 years, according to findings published in Fertility and Sterility.
PCOS beyond fertility: What do patients truly care about?
Historically, much of the medical conversation around polycystic ovary syndrome, which affects 5% to 20% of women worldwide, has centered on fertility, but the condition extends far beyond reproductive health.
Menopausal hormone therapy use fell 82% since 1999, as ‘negative perceptions’ persist
Hormone therapy use markedly declined among postmenopausal women of all ages, races and ethnicities in the U.S. during the past 2 decades, according to findings published in JAMA Health Forum.
Stress, infertility ‘interwoven’ in PCOS, but treatments may improve odds for pregnancy
Women with polycystic ovary syndrome have a higher likelihood of experiencing infertility and subfertility, which can harm mental health and trigger stress, but not everyone with this disorder will require assisted reproduction to conceive.
Hormone therapy use among menopausal women continues to decline, despite proven safety
CHICAGO — Hormone therapy use among menopausal women has fallen to just 1.8% as of 2023, data show, despite evidence and clinical guidance suggesting HT is safe and effective for most women for bothersome menopausal symptoms.
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read